Literature DB >> 30849209

Recurrence patterns after pancreaticoduodenectomy for ampullary cancer.

Hongbeom Kim1, Wooil Kwon1, Jae Ri Kim1, Yoonhyeong Byun1, Jin-Young Jang1, Sun-Whe Kim1.   

Abstract

BACKGROUND: Few studies of the oncological outcomes of ampullary cancer have addressed recurrence, and many treatment-related issues remain unresolved. This study evaluated optimal surgical treatment strategies based on recurrence patterns after pancreaticoduodenectomy (PD) for ampullary cancer.
METHODS: Two hundred and fifty-nine patients who underwent PD with R0 resection for ampullary cancer from January 2000 to June 2012 were included. Generally, lymph node (LN) dissection extended to the right superior mesenteric artery (SMA). Recurrence was defined based on imaging studies. The first detected recurrence sites and patterns were analyzed.
RESULTS: During a mean follow-up of 51.3 months, recurrence occurred in 89 (34.4%) cases, most commonly in the liver. Poor differentiation, advanced T stage, and LN metastasis were identified as risk factors for recurrence. Locoregional and systemic recurrences occurred alone or simultaneously in 20.2%, 73.0%, and 6.7% of patients, respectively. Locoregional and systemic recurrences tended to occur in early- and advanced-stage cases, respectively. A nodal-type recurrence around mesenteric vessels was the most common locoregional recurrence pattern, and 58.8% (10/17) were located left of the SMA.
CONCLUSION: As nodal-type metastasis around the mesenteric vessels was the dominant recurrence pattern, careful LN dissection around the SMA should be considered for early and advanced ampullary cancers.
© 2019 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Ampulla of Vater; Lymph node; Neoplasm; Pancreaticoduodenectomy; Recurrence

Mesh:

Year:  2019        PMID: 30849209     DOI: 10.1002/jhbp.618

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  6 in total

1.  Long-term survival and pattern of recurrence in ampullary adenocarcinoma patients after curative Whipple's resection: a retrospective cohort study in the National Cancer Center in China.

Authors:  Xiaojie Zhang; Chongyuan Sun; Zefeng Li; Tongbo Wang; Lulu Zhao; Penghui Niu; Chunguang Guo; Xu Che; Yingtai Chen; Dongbing Zhao
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

2.  Factors influencing patterns of recurrence following pancreaticoduodenectomy for patients with distal bile duct cancer and ampulla of Vater cancer.

Authors:  Do Hyeon Lee; Hyoung Joo Kim; Chan Woo Cho; Sung Su Yun; Dong-Shik Lee
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-05-31

3.  Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer.

Authors:  Hyeong Min Park; Sang-Jae Park; Sung-Sik Han; Seong Kweon Hong; Eun Kyung Hong; Sun-Whe Kim
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology.

Authors:  Matteo Palmeri; Niccola Funel; Gregorio Di Franco; Niccolò Furbetta; Desirée Gianardi; Simone Guadagni; Matteo Bianchini; Luca E Pollina; Claudio Ricci; Marco Del Chiaro; Giulio Di Candio; Luca Morelli
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

5.  Prognostic importance of numbers of retrieved lymph nodes and positive lymph nodes for ampulla of vater cancer (AVC) in 2347 patients from the Surveillance, Epidemiology, and End Results (SEER) database.

Authors:  Jiao Feng; RuiYang Wu; Gang Zhang; ZhiMing Yang; Liang Zhang
Journal:  PLoS One       Date:  2021-01-15       Impact factor: 3.240

6.  Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study.

Authors:  Eun-Ki Min; Seung Soo Hong; Ji Su Kim; Munseok Choi; Hyeo Seong Hwang; Chang Moo Kang; Woo Jung Lee; Dong Sup Yoon; Ho Kyoung Hwang
Journal:  Ann Surg Oncol       Date:  2021-12-20       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.